13:54 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Cell-penetrating mini-protein targeting MYC for lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Cell culture and mouse studies suggest a cell-penetrating mini-protein targeting MYC-MYC and MYC-MAX interactions could help treat lung cancer. In three human non-small cell lung cancer (NSCLC) cell lines,...
21:47 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

MAX homodimer stabilizer for MYC-driven cancers

DISEASE CATEGORY: Cancer INDICATION: Hematologic malignancies; liver cancer; lung cancer; prostate cancer; pancreatic cancer Cell culture and mouse studies identified a MAX homodimer stabilizer that could help treat MYC-driven ALL, lung, liver and other cancers....
18:48 , Mar 20, 2019 |  BC Extra  |  Preclinical News

Peptomyc study details MYC-targeted cell-penetrating biologic

A new study from Peptomyc provides the latest evidence that cell-penetrating biologics can hit the previously intractable cancer target MYC. In a Science Translational Medicine paper, the company showed its mini-protein targeting MYC can reach...
20:13 , Mar 18, 2019 |  BC Extra  |  Preclinical News

Kronos co-founder, MIT team discover compound that indirectly blocks MYC

An MIT team led by Kronos co-founder Angela Koehler has discovered a small molecule that prevents MYC, an oncogene considered undruggable, from driving gene expression by locking up its binding partner MAX. The transcription factor...
07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer c-Myc (MYC); MYC associated factor X (MAX) In vitro and mouse studies have identified compounds that could inhibit the MYC-MAX interaction and help treat...
08:00 , Feb 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily a member 4 (SMARCA4; BRG1) Cell culture studies suggest inhibiting BRG1 could help treat MYC associated...
07:00 , Jun 30, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Neuroendocrine tumors MYC associated factor X (MAX) Genomic profiling identified mutations in the MAX gene that could help predict the risk of pheochromocytoma, a type...